A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
Clinical trial NCT04489888 · COMPLETED
Trial details
- NCT number
- NCT04489888
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2020-10-27
- Primary completion
- 2023-02-20
- Enrollment
- 101
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.